Review
Biochemistry & Molecular Biology
Jie Wang, Feng Yun, Jiahui Sui, Wenpeng Liang, Dingding Shen, Qi Zhang
Summary: Epilepsy, a common and severe chronic neurological disorder, has been the subject of extensive research on post-translational modification (PTM) mechanisms, particularly protein acetylation modifications. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate acetylation, with HATs transferring acetyl groups to lysine residues and HDACs removing acetyl groups. Epilepsy is associated with the regulation of gene expression through histone acetylation and deacetylation, as well as the acetylation modification of non-histone substrates. HDAC inhibitors (HDACi) have been developed as potential antiepileptic drugs. This review summarizes the changes in acetylation modification during epileptogenesis, the application of HDACi in epilepsy treatment, and the underlying mechanisms. Further understanding of acetylation regulation will provide insights into the pathological mechanism of epilepsy and novel therapeutic ideas.
Article
Chemistry, Medicinal
Yuqi Jiang, Jie Xu, Kairui Yue, Chao Huang, Mengting Qin, Dongyu Chi, Qixin Yu, Yue Zhu, Xiaohan Hou, Tongqiang Xu, Min Li, C. James Chou, Xiaoyang Li
Summary: The study focused on modifying HDAC inhibitors to deactivate the Michael reaction in order to improve their potency. Compound 11h showed significant improvements in both HDAC inhibitory activity and cell-based antitumor assay, demonstrating potential for clinical application and efficacy against AML.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Chemistry, Medicinal
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, Hong-Min Liu
Summary: In this translation, the essential role of HDACs in maintaining homeostasis is discussed, with a focus on the unique characteristics and diverse functions of HDAC6. HDAC6 inhibitors have shown promising potential in treating various diseases with reduced toxicity. Progress has been made in defining the crystal structures of HDAC6 catalytic domains, which can inform the development of HDAC6 inhibitors.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Genetics & Heredity
Miao Yan, Heng Cao, Kangjia Tao, Bing Xiao, Yifan Chu, Ding Ma, Xiaoyuan Huang, Yingyan Han, Teng Ji
Summary: This study explored the role of histone deacetylases (HDACs) in the tumor immune microenvironment of gynecologic tumors. Elevated HDAC expression was associated with poor prognosis and highly malignant cancer subtypes. Increased HDAC expression was linked to reduced infiltration of immune cells and negative associations with certain gene expression, while treatment with HDAC inhibitor and PD-1 antibody inhibited tumor growth and promoted immune microenvironment activation in a breast cancer model.
Review
Cell Biology
Saikat Dewanjee, Jayalakshmi Vallamkondu, Rajkumar Singh Kalra, Pratik Chakraborty, Moumita Gangopadhyay, Ranabir Sahu, Vijaykrishna Medala, Albin John, P. Hemachandra Reddy, Vincenzo De Feo, Ramesh Kandimalla
Summary: Diabetes mellitus is a major manifestation of metabolic syndrome with increasing prevalence. Chronic hyperglycemia can lead to various vascular complications, being the major cause of morbidity and mortality in diabetic patients. Histone deacetylase (HDAC) plays a crucial role in regulating molecular activities in diabetes and could serve as a potential therapeutic target for developing novel intervention strategies.
Article
Engineering, Environmental
Jue Ling, Yi Luo, Cheng Sun, Zhangji Dong, Ronghua Wu, Xiaoxuan Tang, Nan Du, Rui Zhu, Shi Chen, Mei Liu, Yan Liu, Yongjun Wang, Xiaosong Gu, Yong Ling, Yumin Yang
Summary: This study introduces an intraoperative therapeutic strategy using a multifunctional fluorescent probe for highly sensitive and selective real-time diagnosis of micrometastases in zebrafish and mice, and significant tumor inhibition against colon cancer and hepatic metastasis.
CHEMICAL ENGINEERING JOURNAL
(2021)
Article
Chemistry, Physical
Yogesh Mahadu Khetmalis, Bakhya Shree, Boddupalli Venkata Siva Kumar, Markus Schweipert, Cecile Debarnot, Fathima Ashna, Murugesan Sankaranarayanan, Jamma Trinath, Vivek Sharma, Franz -Josef Meyer-Almes, Kondapalli Venkata Gowri Chandra Sekhar
Summary: A series of novel tetrahydroisoquinoline (THIQ) compounds were synthesized and evaluated as selective inhibitors of histone deacetylase 6 (HDAC 6). The compounds demonstrated potent antiproliferative activities and inhibited the colony formation in cancer cells. B10 and B24 showed the highest selectivity towards HDAC 6 with IC50 values of 0.3 μM and 0.4 μM respectively. The inhibition of cancer cell proliferation by B21 and B24 was attributed to cell cycle arrest in G1 phase and apoptotic death of the cancer cells.
JOURNAL OF MOLECULAR STRUCTURE
(2023)
Review
Pharmacology & Pharmacy
Abhishek Wahi, Priti Jain, Apurba Sinhari, Hemant R. Jadhav
Summary: The study of epigenetic translational modifications, particularly the disruption in the expression and activity of histone deacetylases (HDACs), has gained significant interest in the field of cancer research. HDACs play a vital role in various processes that contribute to cancer development and progression. HDAC inhibitors (HDACis), which have been developed as a therapeutic approach, show promising potential in treating cancer with reduced side effects compared to conventional synthetic inhibitors.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Daniel Delgado-Bellido, F. J. Oliver, Maria Victoria Vargas Padilla, Laura Lobo-Selma, Antonio Chacon-Barrado, Juan Diaz-Martin, Enrique de alava
Summary: Tumor growth can be facilitated by the expansion of blood vessels or the development of vasculogenic mimicry (VM), a novel pathway involving aggressive tumor cells expressing endothelial cell markers. VM is associated with high tumor grade, cancer cell invasion, metastasis, and reduced survival. This review summarizes studies on angiogenesis and aberrant angiogenesis by tumor cells, discusses the intracellular signaling mechanisms involved in VM formation, and explores the implications for tumor angiogenesis and targeted therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Medicinal
An-Min Zhou, Meng-Meng Wang, Yan Su, Zheng-Hong Yu, Hong-Ke Liu, Zhi Su
Summary: In this study, a new agent Ir-VPA was developed, which exhibited switching between apoptosis and autophagy in cervical cancer cells due to the inhibition of HDAC6 at different levels. Ir-VPA showed the best anticancer activity to HeLa cells, inducing severe DNA damages and cell cycle arrest at G2/M phase. The anticancer mechanism of Ir-VPA was dependent on the inhibitory performance of HDAC6, with caspase-dependent apoptosis at low concentration and autophagy with autophagy flux blockage at high concentration.
Review
Pharmacology & Pharmacy
Meran Keshawa Ediriweera
Summary: Histone acetylation is a crucial epigenetic event and continues to be an area of great interest in biochemical research. The balance between histone acetyltransferases (HATs) and histone deacetylases (HDACs) is disrupted in various human cancers. Histone deacetylase inhibitors (HDACi) have shown promising results in restoring dysregulated histone acetylation profiles and are considered as potential anti-cancer therapeutics. Recent studies have identified odd-chain fatty acids as novel HDACi, further expanding the understanding of fatty acids in cancer therapy.
DRUG DISCOVERY TODAY
(2023)
Article
Chemistry, Medicinal
Shawn J. Stachel, Deping Wang, Anthony T. Ginnetti, Shahriar Niroomand, Lei Ma, Yinghui Hu, John F. Fay, Wei Lemaire, Daniel J. Krosky, Andres D. Ramirez, Hatim A. Zariwala, Paul J. Coleman
Summary: Virtual screening was used to identify four novel, potent, and highly selective HDAC6 inhibitor series with favorable ligand binding efficiencies and good potential for further optimization.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2023)
Review
Oncology
Robert Jenke, Nina Ressing, Finn K. Hansen, Achim Aigner, Thomas Buch
Summary: Epigenetic changes can drive cancer malignancy, while histone deacetylase inhibitors (HDACis) hold promise as anticancer drugs due to their ability to target multiple pathways relevant to the disease.
Review
Pharmacology & Pharmacy
Ekta Shirbhate, Ravichandran Veerasamy, Sai H. S. Boddu, Amit K. Tiwari, Harish Rajak
Summary: One significant obstacle in cancer treatment is the decrease in drug efficacy and occurrence of adverse effects. Oncolytic viruses (OVs) have gained interest as a potential method to treat cancer due to their specificity for cancerous tissue and reduced likelihood of adverse effects. Clinical trials have shown that OVs have an acceptable safety profile and are effective in treating certain types of cancer, despite their limited availability. However, further advancements are needed to enhance tumor permeation and improve virus delivery in order to make oncolytic virotherapy more effective.
DRUG DISCOVERY TODAY
(2022)
Review
Chemistry, Medicinal
Yunheng Li, Shenghu Sang, Weijie Ren, Yuqiong Pei, Yaoyao Bian, Yao Chen, Haopeng Sun
Summary: The expression of HDAC6 in the hippocampus plays a significant role in the treatment of Alzheimer's disease, as its high expression can be detrimental to neuron survival. Therefore, the inhibition of HDAC6 appears to be a potential therapeutic method for AD.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Editorial Material
Dermatology
Markus Meissner
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2021)
Article
Cardiac & Cardiovascular Systems
Holger M. Nef, Albrecht Elsaesser, Helge Moellmann, Mohammed Abdel-Hadi, Timm Bauer, Martin Brueck, Holger Eggebrecht, Joachim R. Ehrlich, Markus W. Ferrari, Stephan Fichtlscherer, Ulrich Hink, Hans Hoelschermann, Rifat Kacapor, Oliver Koeth, Serguei Korboukov, Steffen Lamparter, Alexander J. Laspoulas, Ralf Lehmann, Christoph Liebetrau, Tobias Pluecker, Joern Pons-Kuehnemann, Volker Schaechinger, Bernhard Schieffer, Peter Schott, Matthias Schulze, Claudius Teupe, Mariuca Vasa-Nicotera, Michael Weber, Christoph Weinbrenner, Gerald Werner, Christian W. Hamm, Oliver Doerr
Summary: During the COVID-19 lockdown period in central Germany, cardiovascular mortality significantly increased while catheterization activities decreased. Further investigations are needed to understand the mechanisms behind these observations.
CLINICAL RESEARCH IN CARDIOLOGY
(2021)
Letter
Oncology
Anja Wessely, Theresa Steeb, Carola Berking, Max Schlaak, Markus V. Heppt, Mareike Alter, Christiane Bayerl, Armin Bender, Guido Bruning, Evelyn Dabrowski, Dirk Debus, Nina Devereux, Edgar Dippel, Konstantin Drexler, Pia Ducker, Reinhard Dummer, Steffen Emmert, Peter Elsner, Alexander Enk, Christoffer Gebhardt, Anja Gesierich, Matthias Goebeler, Sergij Goerdt, Steven Goetze, Ralf Gutzmer, Sebastian Haferkamp, Gesina Hansel, Jessica C. Hassel, Lucie Heinzerling, Katharina C. Kahler, Kjell M. Kaume, Wolfgang Krapf, Nicole Kreuzberg, Percy Lehmann, Elisabeth Livingstone, Harald Loffler, Carmen Loquai, Cornelia Mauch, Johanna Mangana, Friedegund Meier, Markus Meissner, Rose K. C. Moritz, Lara Valeska Maul, Verena Mueller, Peter Mohr, Alexander Navarini, Van Ahn Nguyen, Christiane Pfeiffer, Claudia Pfohler, Christian Posch, Erika Richtig, Rainer Rompel, Michael M. Sachse, Stefanie Sauder, Dirk Schadendorf, Kerstin Schatton, Hans-Joachim Schulze, Erwin Schultz, Bastian Schilling, Matthias Schmuth, Jan. C. Simon, Markus Streit, Patrick Terheyden, Alexander Thiem, Thomas Tuting, Julia Welzel, Gerhard Weyandt, Ulrich Wesselmann, Uwe Wollina, Mirjana Ziemer, Lisa Zimmer, Markus Zutt
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Theresa Steeb, Anja Wessely, Mareike Alter, Christiane Bayerl, Armin Bender, Guido Bruning, Evelyn Dabrowski, Dirk Debus, Nina Devereux, Edgar Dippel, Konstantin Drexler, Pia Duecker, Reinhard Dummer, Steffen Emmert, Peter Elsner, Alexander Enk, Christoffer Gebhardt, Anja Gesierich, Matthias Goebeler, Sergij Goerdt, Steven Goetze, Ralf Gutzmer, Sebastian Haferkamp, Gesina Hansel, Jessica C. Hassel, Lucie Heinzerling, Katharina C. Kaehler, Kjell M. Kaume, Wolfgang Krapf, Nicole Kreuzberg, Percy Lehmann, Elisabeth Livingstone, Harald Loeffler, Carmen Loquai, Cornelia Mauch, Johanna Mangana, Friedegund Meier, Markus Meissner, Rose K. C. Moritz, Lara Valeska Maul, Verena Mueller, Peter Mohr, Alexander Navarini, Ahn Van Nguyen, Christiane Pfeiffer, Claudia Pfoehler, Christian Posch, Erika Richtig, Rainer Rompel, Michael M. Sachse, Stefanie Sauder, Dirk Schadendorf, Kerstin Schatton, Hans-Joachim Schulze, Erwin Schultz, Bastian Schilling, Matthias Schmuth, Jan C. Simon, Markus Streit, Patrick Terheyden, Alexander Thiem, Thomas Tueting, Julia Welzel, Gerhard Weyandt, Ulrich Wesselmann, Uwe Wollina, Mirjana Ziemer, Lisa Zimmer, Markus Zutt, Carola Berking, Max Schlaak, Markus Heppt
Summary: The treatment patterns and surveillance of patients with uveal melanoma in Germany, Austria, and Switzerland are highly variable, indicating an urgent need for a guideline to standardize practices.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Franziska K. Krebs, Emily R. Trzeciak, Sophia Zimmer, Deniz Oezistanbullu, Heidrun Mitzel-Rink, Markus Meissner, Stephan Grabbe, Carmen Loquai, Andrea Tuettenberg
Summary: This study found a distinct immune signature in the peripheral blood of melanoma patients before treatment that could predict response to immune checkpoint inhibitor therapy. Responders to therapy exhibited specific immune cell compositions, but even non-responders with similar compositions still benefited from treatment.
Article
Oncology
Igor Hrgovic, Johannes Kleemann, Monika Doll, Carmen Loquai, Florian Weid, Frank Louwen, Nadja Zoeller, Stefan Kippenberger, Roland Kaufmann, Markus Meissner
Summary: The study found that serum levels of 2-methoxyestradiol (2-ME) in patients with malignant melanoma (MM) were not decreased and did not correlate with disease stage. In contrast to endometrial cancer, 2-ME levels in MM were not found to be a suitable prognostic factor.
MOLECULAR AND CLINICAL ONCOLOGY
(2021)
Article
Dermatology
Alexander Nast, Hans-Martin Haefner, Andreas Kolk, Jurgen Koscielny, Christian Kunte, Christoph Loser, Markus Meissner, Anna Pokrywka, Steffen Schirmer, Fabian David Scherer, Klaus Stromer, Tino Wetzig, Corinna Dressler
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2021)
Article
Dermatology
M. Otto, B. Dorn, T. Grasmik, M. Doll, M. Meissner, T. Jakob, I Hrgovic
Summary: Apremilast effectively inhibits pro-inflammatory responses in activated human umbilical vein endothelial cells, suggesting its therapeutic potential in preventing cardiovascular diseases in patients with chronic inflammatory conditions.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Immunology
Hans Urban, Eike Steidl, Elke Hattingen, Katharina Filipski, Markus Meissner, Martin Sebastian, Agnes Koch, Adam Strzelczyk, Marie-Therese Forster, Peter Baumgarten, Michael W. Ronellenfitsch, Joachim P. Steinbach, Martin Voss
Summary: The use of ICIs in metastatic cancer patients has shown significant survival benefits, but it can also lead to neurological immune related adverse events. In this retrospective analysis, we found that cerebral pseudoprogression occurred in 3.2% of patients receiving ICI treatment, highlighting the importance of vigilance in diagnosis and treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Elias A. T. Koch, Anne Petzold, Anja Wessely, Edgar Dippel, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina C. Kaehler, Harald Knorr, Nicole Kreuzberg, Ulrike Leiter, Carmen Loquai, Friedegund Meier, Markus Meissner, Peter Mohr, Claudia Pfoehler, Farnaz Rahimi, Dirk Schadendorf, Beatrice Schell, Max Schlaak, Patrick Terheyden, Kai-Martin Thoms, Beatrice Schuler-Thurner, Selma Ugurel, Jens Ulrich, Jochen Utikal, Michael Weichenthal, Fabian Ziller, Carola Berking, Markus V. Heppt, German Dermatologic Cooperat Oncol Grp
Summary: The use of immune checkpoint blockade (ICB) in uveal melanoma (UM) patients has shown low response rates, but this retrospective multicenter study provides evidence for the clinical activity of a re-induction with ICB in a small subgroup of patients. The study compares the effectiveness of ICB re-induction with once-only ICB treatment, and it suggests that re-induction of ICB may benefit some UM patients even after resistance or toxicity.
Letter
Dermatology
Kim Nikola Zeiner, Teresa Schreckenbach, Tatjana Gruber-Rouh, Frederik Roos, Johannes Frank, Roland Kaufmann, Markus Meissner, Eva Maria Valesky
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
J. Kleemann, M. Meissner, D. Oezistanbullu, Ue Balaban, O. Old, S. Kippenberger, J. Kloka, R. Kaufmann, K. Zacharowski, B. Friedrichson
Summary: A study in Germany found that skin cancer cases and surgeries have persistently decreased since the beginning of the pandemic. Non-melanoma skin cancer showed a larger decrease compared to malignant melanoma, suggesting a prioritization effect. Further research is needed to understand the consequences of treatment delays and the challenges in skin cancer care.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Oncology
Eleni Zoga, Robert Wolff, Hanns Ackermann, Markus Meissner, Claus Rodel, Nikolaos Tselis, Georgios Chatzikonstantinou
Summary: This retrospective analysis investigated factors associated with hemorrhage (HA) of melanoma brain metastases (MBM) after robotic stereotactic radiosurgery (SRS). The use of anticoagulants was the only predictive factor for radiologically evident HA and HA causing grade 3 toxicity. The time interval between systemic therapy and SRS was also significant in relation to HA causing grade 1 toxicity. This study contributes to the understanding of factors related to HA.
Article
Dermatology
D. Oezistanbullu, R. Weber, J. Kleemann, M. Jaeger, S. Kippenberger, R. Kaufmann, M. Meissner
Summary: This study investigated the quality and reliability of online information on CTCL and found major shortcomings in terms of readability and completeness. However, selected websites on CTCL can still serve as valuable and reliable sources of patient information.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Oncology
Johannes Kleemann, Katja Steinhorst, Veronika Koenig, Nadja Zoller, Jindrich Cinatl Jr, Deniz Oezistanbullu, Roland Kaufmann, Markus Meissner, Stefan Kippenberger
Summary: The study found that oligonucleotides (ODNs) can suppress the expression of PD-L1/2 in melanoma cells, particularly a sequence containing solely guanines (nCpG-6-PTO) was highly effective. By suppressing the interferon signaling axis, these ODNs may serve as interesting pharmacological compounds to expand targeted therapies for immunological escape of tumor cells.
Article
Dermatology
Matthew J. Davis, Gokul Srinivasan, Rachael Chacko, Sophie Chen, Anish Suvarna, Louis J. Vaickus, Veronica C. Torres, Sassan Hodge, Eunice Y. Chen, Sarah Preum, Kimberley S. Samkoe, Brock C. Christensen, Matthew R. Leboeuf, Joshua J. Levy
Summary: The development and application of AI algorithms are of great significance for the removal of cSCC, as they can improve operational efficiency and accuracy, especially for moderately and poorly differentiated tumors/ neoplasms. Further improvement is needed to maintain sensitivity to surrounding tissue and determine anatomical positioning.
EXPERIMENTAL DERMATOLOGY
(2024)
Article
Dermatology
Lingjing Chen, Qing Yu, Feiying Guo, Xuewen Wang, Zhenying Cai, Qiang Zhou
Summary: This study investigated the role and mechanisms of NTS in stress-induced hair growth inhibition. The results demonstrated that NTS effectively counteracted hair growth inhibition caused by stress and regulated the expression of multiple genes related to hair growth at the transcriptional level.
EXPERIMENTAL DERMATOLOGY
(2024)